| Literature DB >> 24804010 |
Trina J Lapis1, Alexandra C M Oliveira1, Charles A Crapo1, Brian Himelbloom1, Peter J Bechtel2, Kristy A Long3.
Abstract
Establishing n-3 polyunsaturated fatty acid contents in canned wild Alaska pink salmon products is challenging due to ample natural variation found in lipid content of pink salmon muscle. This study investigated the effect of adding salmon oil (SO) to canned pink salmon produced from fish exhibiting two opposite degrees of skin watermarking, bright (B) and dark (D). Specific goals of the study were to evaluate the benefits of adding SO to canned pink salmon with regard to nutritional value of the product, sensory characteristics, and the oxidative and hydrolytic stability of the lipids over thermal processing. Six groups of canned pink salmon were produced with variable levels of SO, either using bright (with 0, 1, or 2% SO) or dark (with 0, 2, or 4% SO) pink salmon. Compositional analysis revealed highest (P < 0.05) lipid content in sample B2 (8.7%) and lowest (P < 0.05) lipid content in sample D0 (3.5%). Lipid content of samples B0, B1, D2, and D4 was not significantly different (P > 0.05) ranging from 5.7% to 6.8%. Consequently, addition of SO to canned pink salmon allowed for consistent lipid content between bright and dark fish. Addition of 1% or 2% SO to canned bright pink salmon was not detrimental to the sensory properties of the product. It is recommended that canned bright pink salmon be supplemented with at least 1% SO, while supplementation with 2% SO would guarantee a minimum quantity of 1.9 g of n-3 fatty acids per 100 g of product. Addition of 4% SO to canned dark pink salmon was detrimental to product texture and taste, while supplementation with 2% SO did not negatively affect sensorial properties of the product. Accordingly, canned dark pink salmon should be supplemented with 2% SO so that a minimum n-3 fatty acids content of 1.5 g per 100 g of product.Entities:
Keywords: Canned salmon; Pacific salmon; salmon oil; seafood composition
Year: 2013 PMID: 24804010 PMCID: PMC3951564 DOI: 10.1002/fsn3.4
Source DB: PubMed Journal: Food Sci Nutr ISSN: 2048-7177 Impact factor: 2.863
Proximate composition (% w/w ± SD) of canned Alaska pink salmon with different levels of salmon oil
| B0 ( | B1 ( | B2 ( | D0 ( | D2 ( | D4 ( | |
|---|---|---|---|---|---|---|
| Moisture | 71.0c ± 0.4 | 70.7c ± 0.7 | 69.0d ± 1.2 | 74.4a ± 0.2 | 72.5b ± 0.6 | 72.2b ± 0.4 |
| Protein | 20.5a ± 0.3 | 20.1ab ± 0.2 | 19.6bc ± 0.2 | 19.2c ± 0.1 | 18.9cd ± 0.1 | 18.1d ± 0.1 |
| Lipid | 5.8b ± 1.2 | 6.5b ± 1.6 | 8.7a ± 2.4 | 3.5c ± 0.6 | 5.7b ± 0.6 | 6.8b ± 0.6 |
| Ash | 2.6b ± 0.8 | 2.7ab ± 0.9 | 2.7ab ± 1.0 | 2.9a ± 0.4 | 2.9a ± 0.4 | 2.9a ± 0.5 |
| Salt | 1.36c ± 0.11 | 1.38bc ± 0.22 | 1.46abc ± 0.22 | 1.57ab ± 0.09 | 1.63a ± 0.12 | 1.48abc ± 0.16 |
Treatments are canned bright pink salmon with 0% (B0), 1% (B1), and 2% (B2) human-grade salmon oil, and canned dark pink salmon with 0% (D0), 2% (D2), and 4% (D4) human-grade salmon oil. Different superscript letters within a row indicate significant differences (P < 0.05); SD standard deviation of the mean.
Fatty acid profiles of salmon oil (mg/g oil) and canned bright and dark pink salmon with different levels of salmon oil (mg/100 g of products ± SD)
| SO ( | B0 ( | B1 ( | B2 ( | D0 ( | D2 ( | D4 ( | |
|---|---|---|---|---|---|---|---|
| 14:0 | 44.92 | 203b ± 45 | 203b ± 68 | 296a ± 85 | 85c ± 24 | 209b ± 26 | 213b ± 43 |
| 16:0 | 117.18 | 589b ± 102 | 581b ± 189 | 856a ± 191 | 297c ± 87 | 612b ± 62 | 625b ± 122 |
| 16:1n-7 | 37.33 | 141cd ± 30 | 136d ± 40 | 230a ± 50 | 78e ± 25 | 191ab ± 24 | 181bc ± 37 |
| 18:0 | 24.15 | 103b ± 12 | 105b ± 26 | 153a ± 33 | 54c ± 18 | 121b ± 12 | 122b ± 24 |
| 18:1 | 6.88 | 53ab ± 13 | 51ab ± 16 | 67a ± 22 | 22c ± 8 | 51ab ± 6 | 43b ± 9 |
| 18:1 | 120.08 | 436c ± 77 | 477bc ± 142 | 729a ± 150 | 247d ± 84 | 579b ± 65 | 589b ± 115 |
| 18:1 | 18.33 | 89bc ± 20 | 95b ± 41 | 132a ± 21 | 57c ± 19 | 108ab ± 18 | 108ab ± 21 |
| 18:2 | 5.48 | 35b ± 8 | 33b ± 11 | 53a ± 15 | 15c ± 4 | 37b ± 5 | 33b ± 8 |
| 18:2 | 13.40 | 71b ± 12 | 67b ± 21 | 101a ± 28 | 34c ± 12 | 77b ± 9 | 73b ± 15 |
| 18:3 | 12.35 | 55b ± 10 | 55b ± 17 | 84a ± 24 | 26c ± 9 | 66b ± 7 | 63b ± 13 |
| 18:4 | 23.20 | 103bc ± 41 | 103bc ± 35 | 166a ± 53 | 59c ± 22 | 137ab ± 23 | 122b ± 28 |
| 20:1 | 42.52 | 392ab ± 130 | 413ab ± 157 | 509a ± 234 | 144c ± 49 | 301bc ± 52 | 303bc ± 73 |
| 20:1 | 21.46 | 137b ± 36 | 141b ± 45 | 187a ± 60 | 62c ± 22 | 130b ± 21 | 123b ± 24 |
| 20:4 | 15.67 | 68b ± 14 | 71b ± 21 | 105a ± 29 | 32c ± 11 | 81b ± 10 | 78b ± 16 |
| 20:5 | 92.86 | 344b ± 81 | 332b ± 110 | 534a ± 112 | 179c ± 54 | 394b ± 42 | 419b ± 85 |
| 22:1 | 57.98 | 424ab ± 116 | 431ab ± 146 | 571a ± 244 | 181c ± 73 | 396b ± 75 | 353bc ± 76 |
| 22:1 | 13.33 | 34b ± 10 | 38b ± 11 | 60a ± 16 | 18c ± 7 | 53a ± 8 | 54a ± 10 |
| 22:5 | 24.23 | 91d ± 12 | 93cd ± 24 | 139a ± 22 | 49e ± 17 | 116ab ± 13 | 115bc ± 23 |
| 22:6 | 99.35 | 598b ± 66 | 583b ± 133 | 851a ± 212 | 354c ± 117 | 649b ± 47 | 641b ± 124 |
| 24:1 | 6.14 | 40b ± 9 | 40b ± 12 | 58a ± 19 | 20c ± 6 | 43b ± 5 | 39b ± 9 |
| DHA/EPA | 1.1 | 1.8ab ± 0.4 | 1.8ab ± 0.3 | 1.6b ± 0.1 | 2.0a ± 0.2 | 1.7ab ± 0.1 | 1.5b ± 0.1 |
Treatments are canned bright pink salmon with 0% (B0), 1% (B1), and 2% (B2) human-grade salmon oil, and canned dark pink salmon with 0% (D0), 2% (D2), and 4% (D4) human-grade salmon oil. Values of less than 35 mg/100 g of product were not reported as individual fatty acids. Different superscript letters within a row indicate significant differences (P < 0.05). SD, standard deviation of the mean; EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid.
Summary of the fatty acid classes and contents of EPA and DHA in canned bright and dark pink salmon with different levels of salmon oil (g/100 g product ± SD)
| B0 ( | B1 ( | B2 ( | D0 ( | D2 ( | D4 ( | |
|---|---|---|---|---|---|---|
| ΣSAT | 1.0b ± 0.2 | 1.0b ± 0.3 | 1.4a ± 0.3 | 0.5c ± 0.1 | 1.1b ± 0.1 | 1.1b ± 0.2 |
| ΣMUFA | 1.9b ± 0.3 | 1.9b ± 0.6 | 2.7a ± 0.8 | 0.9c ± 0.3 | 2.0b ± 0.2 | 1.9b ± 0.4 |
| ΣPUFA | 1.4b ± 0.2 | 1.4b ± 0.4 | 2.1a ± 0.5 | 0.8c ± 0.2 | 1.6b ± 0.1 | 1.6b ± 0.3 |
| EPA+DHA | 0.9b ± 0.1 | 0.9b ± 0.2 | 1.4a ± 0.3 | 0.5c ± 0.2 | 1.0b ± 0.1 | 1.1b ± 0.2 |
| Σ | 1.3b ± 0.2 | 1.2b ± 0.3 | 1.9a ± 0.4 | 0.7c ± 0.2 | 1.5b ± 0.1 | 1.4b ± 0.3 |
Treatments are canned bright pink salmon with 0% (B0), 1% (B1), and 2% (B2) human-grade salmon oil, and canned dark pink salmon with 0% (D0), 2% (D2), and 4% (D4) human-grade salmon oil. Different superscript letters within a row indicate significant differences (P < 0.05). SD, standard deviation of the mean; SAT, saturated fatty acids; MUFA, monounsaturated fatty acids; PUFA, polyunsaturated fatty acids; EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid.
Figure 1Lipid damage indices of salmon oil (SO; n = 1), and canned bright (B; n = 12) and dark (D; n = 12) Alaska pink salmon with different levels (0, 1, 2, or 4%) of salmon oil added to cans. (A) Free fatty acid values (FFA), (B) Peroxide-values (PV), (C) 2-thiobarbituric acid (TBA) values.
Mean scores of sensory attributes (±SD) of the six sensory comparisons
| Set | Comparison | Sample | Color | Overall taste | Bitterness | Fattiness | Fish flavor | Texture |
|---|---|---|---|---|---|---|---|---|
| 1 | B0 vs. B1 vs. B2 | B0 | 7.5a ± 3.3 | 9.2a ± 3.0 | 4.6a ± 3.8 | 5.7a ± 3.3 | 8.2a ± 3.1 | 7.4a ± 3.1 |
| B1 | 8.2a ± 3.7 | 9.1a ± 3.1 | 4.1a ± 3.1 | 5.7a ± 3.5 | 8.0a ± 3.1 | 7.8a ± 3.6 | ||
| B2 | 7.1a ± 3.4 | 8.6a ± 3.3 | 4.2a ± 3.0 | 6.1a ± 3.3 | 8.2a ± 3.3 | 7.0a ± 3.4 | ||
| 2 | D0 vs. D2 vs. D4 | D0 | 8.1a ± 3.4 | 8.9a ± 3.1 | 3.9a ± 3 | 5.6b ± 3.3 | 8.0b ± 3.1 | 6.8ab ± 3.2 |
| D2 | 7.6a ± 3.2 | 9.1a ± 3.2 | 3.7a ± 3.1 | 6.1b ± 3.0 | 8.6ab ± 3.0 | 7.4a ± 3.5 | ||
| D4 | 8.5a ± 3.1 | 8.9a ± 3.2 | 3.8a ± 3.1 | 7.5a ± 3.8 | 9.1a ± 2.9 | 6.1b ± 3.3 | ||
| 3 | B0 vs. D0 | B0 | 8.1a ± 3.2 | 8.6a ± 3.1 | 3.2b ± 2.4 | 5.2b ± 2.7 | 7.4b ± 3.1 | 7.7a ± 3.5 |
| D0 | 6.5b ± 3.1 | 6.6b ± 3.5 | 4.6a ± 3.5 | 6.3a ± 3.2 | 8.1a ± 3.5 | 5.3b ± 3.3 | ||
| 4 | B1 vs. D2 | B1 | 8.3a ± 3.0 | 9.0a ± 2.9 | 3.4b ± 2.6 | 5.6b ± 3.2 | 7.6b ± 3.0 | 7.6a ± 3.4 |
| D2 | 6.3b ± 3.0 | 6.1b ± 3.6 | 5.1a ± 3.9 | 6.9a ± 3.4 | 9.0a ± 3.3 | 4.6b ± 2.9 | ||
| 5 | B2 vs. D4 | B2 | 8.5a ± 3.1 | 9.9a ± 2.9 | 3.7b ± 2.9 | 4.8b ± 2.8 | 8.2b ± 2.9 | 8.3a ± 3.1 |
| D4 | 5.8b ± 2.9 | 6.3b ± 3.6 | 5.6a ± 4.0 | 7.2a ± 3.5 | 9.3a ± 3.3 | 5.1b ± 3.2 | ||
| 6 | B2 vs. D2 | B2 | 8.8a ± 3.0 | 10.0a ± 2.9 | 3.9b ± 3.1 | 5.7b ± 3.3 | 7.6b ± 3.2 | 8.4a ± 3.1 |
| D2 | 6.5b ± 3.4 | 7.6b ± 3.4 | 5.2a ± 4.0 | 7.1a ± 3.5 | 9.0a ± 2.9 | 5.8b ± 3.1 |
Treatments are canned bright pink salmon with 0% (B0), 1% (B1), and 2% (B2) human-grade salmon oil, and canned dark pink salmon with 0% (D0), 2% (D2), and 4% (D4) human-grade salmon oil. Different superscript letters within a column per set of comparison indicate significant difference (P < 0.05); SD standard deviation of the mean.